Researchers analyzed the antibody response induced by the new bivalent mRNA SARS-CoV-2 vaccines in individuals who have been fully vaccinated with monovalent vaccines and those who have had breakthrough infection with the SARS-CoV-2 Omicron BA.4/BA.5 variants.